Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease.

[en] OBJECTIVE: Altered microbiota composition, changes in immune responses and impaired intestinal barrier functions are observed in IBD. Most of these features are controlled by proteases and their inhibitors to maintain gut homeostasis. Unrestrained or excessive proteolysis can lead to pathological gastrointestinal conditions. The aim was to validate the identified protease IBD candidates from a previously performed systematic review through a genetic association study and functional follow-up. DESIGN: We performed a genetic association study in a large multicentre cohort of patients with Crohn's disease (CD) and UC from five European IBD referral centres in a total of 2320 CD patients, 2112 UC patients and 1796 healthy controls. Subsequently, we did an extensive functional assessment of the candidate genes to explore their causality in IBD pathogenesis. RESULTS: Ten single nucleotide polymorphisms (SNPs) in four genes were significantly associated with CD: CYLD, USP40, APEH and USP3. CYLD was the most significant gene with the intronically located rs12324931 the strongest associated SNP (pFDR=1.74e-17, OR=2.24 (1.83 to 2.74)). Five SNPs in four genes were significantly associated with UC: USP40, APEH, DAG1 and USP3. CYLD, as well as some of the other associated genes, is part of the ubiquitin proteasome system (UPS). We therefore determined if the IBD-associated adherent-invasive Escherichia coli (AIEC) can modulate the UPS functioning. Infection of intestinal epithelial cells with the AIEC LF82 reference strain modulated the UPS turnover by reducing poly-ubiquitin conjugate accumulation, increasing 26S proteasome activities and decreasing protein levels of the NF-kappaB regulator CYLD. This resulted in IkappaB-alpha degradation and NF-kappaB activation. This activity was very important for the pathogenicity of AIEC since decreased CYLD resulted in increased ability of AIEC LF82 to replicate intracellularly. CONCLUSIONS: Our results reveal the UPS, and CYLD specifically, as an important contributor to IBD pathogenesis, which is favoured by both genetic and microbial factors.

Disciplines :

Genetics & genetic processes

Author, co-author :

Cleynen, Isabelle

Vazeille, Emilie

Artieda, Marta

Verspaget, Hein W.

Szczypiorska, Magdalena

Bringer, Marie-Agnes

Lakatos, Peter L.

Seibold, Frank

Parnell, Kirstie

Weersma, Rinse K.

More authors (16 more)

Language :

English

Title :

Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease.

Publication date :

2013

Journal title :

Gut

ISSN :

0017-5749

eISSN :

1468-3288

Publisher :

BMJ Publishing Group, United Kingdom

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 19 April 2014

Statistics

Number of views

69 (2 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5):1-16.
Anderson CA, Boucher G, Lees CW, et al. Meta- Analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-52.
Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-62.
Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta- Analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2011;42:1118-25.
Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011;60:631-17.
Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54. (Pubitemid 34049193)
Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-13. (Pubitemid 28545991)
Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004;127:80-93. (Pubitemid 38962277)
Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004;127:412-21. (Pubitemid 39091889)
Boudeau J, Glasser AL, Masseret E, et al. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun 1999;67:4499-509. (Pubitemid 29400425)
Glasser AL, Boudeau J, Barnich N, et al. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001;69:5529-37. (Pubitemid 32786488)
Carvalho FA, Barnich N, Sivignon A, et al. Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009;206:2179-89.
Kaser A, Blumberg RS. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology 2011;140:1738-47.
Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636-47. (Pubitemid 46348522)
Cleynen I, Juni P, Bekkering GE, et al. Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: A systematic review. PLoS One 2011;6:e24106.
Boudeau J, Barnich N, Darfeuille-Michaud A. Type 1 pili-mediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells. Mol Microbiol 2001;39:1272-84. (Pubitemid 32225137)
Chassaing B, Rolhion N, et al. Crohn disease- Associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest 2011;121:966-75.
Claret L, Miquel S, Vieille N, et al. The flagellar sigma factor FliA regulates adhesion and invasion of Crohn disease- Associated Escherichia coli via a cyclic dimeric GMP-dependent pathway. J Biol Chem 2007;282:33275-83. (Pubitemid 350159501)
Dreux N, Denizot J, Martinez-Medina M, et al. Point mutations in FimH adhesin of Crohn's disease- Associated adherent-invasive Escherichia coli enhance intestinal inflammatory response. PLoS Pathog 2013;9:e1003141.
Rolhion N, Carvalho FA, Darfeuille-Michaud A. OmpC and the sigma(E) regulatory pathway are involved in adhesion and invasion of the Crohn's disease- Associated Escherichia coli strain LF82. Mol Microbioly 2007;63:1684-700. (Pubitemid 46426710)
Stegmeier F, Sowa ME, Nalepa G, et al. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 2007;104:8869-74. (Pubitemid 47175403)
An J, Mo D, Liu H, et al. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell 2008;14:394-407.
Koga T, Lim JH, Jono H, et al. Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling. J Biol Chem 2008;283:12546-54.
Lim JH, Stirling B, Derry J, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007;27:349-60. (Pubitemid 47284927)
Costello CM, Mah N, Hasler R, et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2005;2:e199.
Lim JH, Jono H, Koga T, et al. Tumor suppressor CYLD acts as a negative regulator for non- Typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One 2007;2:e1032.
Pan ZK, Fisher C, Li JD, et al. Bacterial LPS up-regulated TLR3 expression is critical for antiviral response in human monocytes: evidence for negative regulation by CYLD. Int Immunol 2011;23:357-64.
Lim JH, Ha UH, Woo CH, et al. CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia. Cell Microbiol 2008;10:2247-56.
Sun SC. CYLD: A tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010;17:25-34.
Saeki Y, Tanaka K. Assembly and function of the proteasome. Methods Mol Biol 2012;832:315-37.
Viatour P, Merville MP, Bours V, et al. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005;30:43-52. (Pubitemid 40093740)
Zhang J, Stirling B, Temmerman ST, et al. Impaired regulation of NF-kappaB and increased susceptibility to colitis- Associated tumorigenesis in CYLD-deficient mice. J Clin Invest 2006;116:3042-9. (Pubitemid 44684489)
Hugot JP, Zouali H, Lesage S. Lessons to be learned from the NOD2 gene in Crohn's disease. Eur J Gastroenterol Hepatol 2003;15:593-7. (Pubitemid 36688221)
Hampe J, Frenzel H, Mirza MM, et al. Evidence for a NOD2-independent susceptibility locus for inflammatory bowel disease on chromosome 16p. Proc Natl Acad Sci USA 2002;99:321-6. (Pubitemid 34060361)
Elding H, Lau W, Swallow DM, et al. Dissecting the genetics of complex inheritance: linkage disequilibrium mapping provides insight into crohn disease. Am J Hum Genet 2011;89:798-805.
Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011;43:1066-73.
Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003;424:801-5. (Pubitemid 37021712)
Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003;424:793-6. (Pubitemid 37021710)
Brest P, Lapaquette P, Souidi M, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet 2011;43:242-5.
Lapaquette P, Glasser AL, Huett A, et al. Crohn's disease- Associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol 2010;12:99-113.
Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 2006;3:255-61.
Nikolaidis NM, Gray JK, Gurusamy D, et al. Ron receptor tyrosine kinase negatively regulates TNF alpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production. Shock 2010;33:197-204.
Xiao N, Li H, Luo J, et al. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNF alpha-induced cancer cell migration. Biochem J 2012;441:979-86.
Fan YH, Yu Y, Mao RF, et al. USP4 targets TAK1 to downregulate TNF alpha-induced NF-kappaB activation. Cell Death Differ 2011;18:1547-60.